GCP
RCUS icon

GSA Capital Partners’s Arcus Biosciences RCUS Stock Holding History

GSA Capital Partners’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32,692
Closed -$779K – 2088
2025
Q4 		$779K Buy
+32,692
New +$667K 0.07% 511
2025
Q3 		– Sell
-116,461
Closed -$948K – 2020
2025
Q2 		$948K Sell
116,461
-79,790
-41% -$682K 0.07% 490
2025
Q1 		$1.54M Buy
196,251
+124,701
+174% +$1.45M 0.14% 150
2024
Q4 		$1.06M Sell
71,550
-115,865
-62% -$1.89M 0.08% 368
2024
Q3 		$2.87M Buy
187,415
+28,307
+18% +$446K 0.22% 42
2024
Q2 		$2.42M Buy
+159,108
New +$2.57M 0.17% 95
2024
Q1 		– Sell
-90,873
Closed -$1.74M – 1905
2023
Q4 		$1.74M Buy
90,873
+69,735
+330% +$1.11M 0.15% 161
2023
Q3 		$379K Buy
+21,138
New +$425K 0.03% 957
2023
Q2 		– Sell
-20,886
Closed -$381K – 1872
2023
Q1 		$381K Sell
20,886
-9,222
-31% -$176K 0.04% 882
2022
Q4 		$623K Buy
+30,108
New +$828K 0.08% 465
2022
Q3 		– Sell
-9,888
Closed -$251K – 1803
2022
Q2 		$251K Sell
9,888
-5,921
-37% -$145K 0.04% 934
2022
Q1 		$499K Buy
15,809
+9,599
+155% +$322K 0.07% 535
2021
Q4 		$251K Buy
+6,210
New +$241K 0.03% 1067
2020
Q4 		– Sell
-31,217
Closed -$535K – 1528
2020
Q3 		$535K Buy
31,217
+21,800
+231% +$487K 0.09% 350
2020
Q2 		$233K Sell
9,417
-23,902
-72% -$645K 0.13% 272
2020
Q1 		$462K Sell
33,319
-37,300
-53% -$464K 0.12% 210
2019
Q4 		$713K Buy
70,619
+31,265
+79% +$263K 0.08% 412
2019
Q3 		$358K Buy
39,354
+23,111
+142% +$186K 0.05% 771
2019
Q2 		$129K Buy
16,243
+2,392
+17% +$23.9K 0.01% 1314
2019
Q1 		$173K Buy
+13,851
New +$150K 0.02% 1265

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

GSA Capital Partners's RCUS Position: Q1 2026 in Review

GSA Capital Partners sold out of Arcus Biosciences (RCUS) in Q1 2026, closing a stake of 32,692 shares — an estimated $779K sold.

GSA Capital Partners first reported a position in RCUS in Q1 2019 and held it in 20 quarters. The position peaked at $2.87M in Q3 2024. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • GSA Capital Partners reported no remaining Arcus Biosciences position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 32,692 Arcus Biosciences shares in Q1 2026, an estimated $779K.
  • GSA Capital Partners first reported a position in Arcus Biosciences in Q1 2019 and held it in 20 quarters.
  • GSA Capital Partners's Arcus Biosciences position peaked at $2.87M in Q3 2024.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.